SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Mar 6, 2019
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: March 6, 2019 · CIK: 0001213037 · Accession: 0001193125-19-066071
AI Filing Summary & Sentiment
File numbers found in text: 333-229693
Letter
Acceleration Request
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
March 6, 2019
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Donald Field
Re: Trovagene, Inc.
Form S-3
File No. 333-229693
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Friday, March 8, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
Thank you,
TROVAGENE, INC.
By:
/s/ Thomas Adams
Name:
Thomas Adams
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request Trovagene, Inc. 11055 Flintkote Avenue San Diego, CA 92121 March 6, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Donald Field Re: Trovagene, Inc. Form S-3 File No. 333-229693 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Friday, March 8, 2019, or as soon thereafter as possible. Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. Thank you, TROVAGENE, INC. By: /s/ Thomas Adams Name: Thomas Adams Title: Chief Executive Officer